Evidence map›Paper›PMID 34683938›Full record

ReviewPharmaceutics2021

Aptamers in Virology-A Consolidated Review of the Most Recent Advancements in Diagnosis and Therapy.

Tejabhiram Yadavalli, Ipsita Volety, Deepak Shukla

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tejabhiram YadavalliDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0001-8584-2685
Ipsita VoletyDepartment of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0001-9200-7944
Deepak ShuklaDepartment of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-3039-6953
University of Illinois Chicago · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCANANY, JAMES JASON · 1985 to 2025
$14.8M
A new molecular therapy against ocular herpesR01EY024710 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2015 to 2026
$5.2M
A small molecule inhibitor of HSV genital infectionsR01AI139768 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 2018 to 2021
$1.6M
NEI NIH HHS EY024710NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY024710NIAID NIH HHS R01 AI139768
6 · The paper itself

Abstract

The use of short oligonucleotide or peptide molecules as target-specific aptamers has recently garnered substantial attention in the field of the detection and treatment of viral infections. Based on their high affinity and high specificity to desired targets, their use is on the rise to replace antibodies for the detection of viruses and viral antigens. Furthermore, aptamers inhibit intracellular viral transcription and translation, in addition to restricting viral entry into host cells. This has opened up a plethora of new targets for the research and development of novel vaccines against viruses. Here, we discuss the advances made in aptamer technology for viral diagnosis and therapy in the past decade.

Indexed as

aptamersdiagnosisSELEXtherapyviruses

Identifiers

PMID34683938
PMCPMC8540715
OpenAlexW3205392314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.